[go: up one dir, main page]

PE20081491A1 - Composicion farmaceutica que comprende (r)-5,6-dimetoxi-2-[2,2,4,6,7-pentametil-3-(4-metilfenil)-2,3-dihidro-1-benzofuran-5-il)isoindolina y un componente lipofilico - Google Patents

Composicion farmaceutica que comprende (r)-5,6-dimetoxi-2-[2,2,4,6,7-pentametil-3-(4-metilfenil)-2,3-dihidro-1-benzofuran-5-il)isoindolina y un componente lipofilico

Info

Publication number
PE20081491A1
PE20081491A1 PE2007001543A PE2007001543A PE20081491A1 PE 20081491 A1 PE20081491 A1 PE 20081491A1 PE 2007001543 A PE2007001543 A PE 2007001543A PE 2007001543 A PE2007001543 A PE 2007001543A PE 20081491 A1 PE20081491 A1 PE 20081491A1
Authority
PE
Peru
Prior art keywords
lipophilic component
dimetoxy
isoindoline
pentamethyl
benzofuran
Prior art date
Application number
PE2007001543A
Other languages
English (en)
Inventor
Satoshi Iinuma
Kazuhisa Kamikawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20081491A1 publication Critical patent/PE20081491A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE A) (R)-5,6-DIMETOXI-2-[2,2,4,6,7-PENTAMETIL-3-(4-METILFENIL)-2,3-DIHIDRO-1-BENZOFURAN-5-IL)ISOINDOLINA EN UNA CANTIDAD DE 1 A 30% EN PESO; B) UN COMPONENTE LIPOFILICO SELECCIONADO DE ESTER DE GLICERINA DE ACIDO GRASO, ESTER DE POLIETILENGLICOL DE ACIDO GRASO, Y UNA DE SUS MEZCLAS Y C) UN AGENTE TENSIOACTIVO TAL COMO ACEITE DE RICINO DE POLIOXIETILENO HIDROGENADO; EN DONDE LA RELACION DEL COMPONENTE LIPOFILICO Y EL TENSIOACTIVO ES DE 1:10 A 10:1, SIENDO PREFERIDA LA FORMA DE CAPSULA. ESTA COMPOSICION PRESENTA ABSORBABILIDAD MEJORADA, SIN SER AFECTADA POR LA CANTIDAD Y CALIDAD DE LA COMIDA
PE2007001543A 2006-11-09 2007-11-08 Composicion farmaceutica que comprende (r)-5,6-dimetoxi-2-[2,2,4,6,7-pentametil-3-(4-metilfenil)-2,3-dihidro-1-benzofuran-5-il)isoindolina y un componente lipofilico PE20081491A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006303800 2006-11-09

Publications (1)

Publication Number Publication Date
PE20081491A1 true PE20081491A1 (es) 2008-11-12

Family

ID=38942774

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001543A PE20081491A1 (es) 2006-11-09 2007-11-08 Composicion farmaceutica que comprende (r)-5,6-dimetoxi-2-[2,2,4,6,7-pentametil-3-(4-metilfenil)-2,3-dihidro-1-benzofuran-5-il)isoindolina y un componente lipofilico

Country Status (11)

Country Link
US (1) US20100273852A1 (es)
EP (1) EP2079455B1 (es)
JP (1) JP2010509188A (es)
AR (1) AR063618A1 (es)
AT (1) ATE456365T1 (es)
CA (1) CA2668864A1 (es)
CL (1) CL2007003217A1 (es)
DE (1) DE602007004642D1 (es)
PE (1) PE20081491A1 (es)
TW (1) TW200833374A (es)
WO (1) WO2008056822A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3291872A4 (en) 2015-05-06 2019-02-13 SynAgile Corporation PHARMACEUTICAL SUSPENSIONS WITH ACTIVE SUBSTANCES, DEVICES FOR THEIR ADMINISTRATION AND METHOD FOR THEIR USE
CN112020359A (zh) 2018-02-09 2020-12-01 分贝治疗公司 含有抗铂化学保护剂的高渗药物组合物
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
DE69915508T2 (de) * 1998-12-04 2005-01-27 Takeda Chemical Industries, Ltd. Benzofuranderivate, verfahren zu ihrer herstellung und deren verwendungen
AU2001244614A1 (en) * 2000-04-04 2001-10-15 Shionogi & Co., Ltd. Oily compositions containing highly fat-soluble drugs
US6878831B2 (en) * 2000-12-28 2005-04-12 Takeda Chemical Industries, Ltd. Process for preparing optically active 2,3-dihydrobenzofuran compounds
EP1457207A4 (en) * 2001-12-19 2008-05-28 Takeda Pharmaceutical SOLID COMPOSITIONS WITH OXYGEN INSTABILITY COMPOUNDS AND STABILIZATION METHOD THEREFOR
EP1481679B1 (en) * 2002-03-01 2010-08-25 Takeda Pharmaceutical Company Limited Antidepressant

Also Published As

Publication number Publication date
EP2079455B1 (en) 2010-01-27
CA2668864A1 (en) 2008-05-15
JP2010509188A (ja) 2010-03-25
ATE456365T1 (de) 2010-02-15
EP2079455A1 (en) 2009-07-22
US20100273852A1 (en) 2010-10-28
TW200833374A (en) 2008-08-16
CL2007003217A1 (es) 2008-07-04
DE602007004642D1 (de) 2010-03-18
WO2008056822A1 (en) 2008-05-15
AR063618A1 (es) 2009-02-04

Similar Documents

Publication Publication Date Title
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
AR078195A1 (es) Composicion antitranspirante y desodorante
CL2010000935A1 (es) Compuestos derivados de niacina unida a un acido graso; composicion farmaceutica que los comprende; y su uso para tratar una enfermedad metabolica tal como hipertrigliceridemia, hipercolesterolemia, diabetes tipo 2 y retinopatia diabetica.
CO6470839A2 (es) Composiciones farmacéuticas que contienen epa y un agente cardiovascular y métodos de emplearlas
PE20141998A1 (es) Composiciones topicas que comprenden fipronilo y permetrina y sus metodos de uso
EA201170433A1 (ru) Полисахаридная капсула, включающая в себя эмульсию, содержащую масло жирных кислот
EA201171113A1 (ru) Композиции, содержащие масляную смесь жирных кислот и поверхностно-активное вещество, способы и применения композиций
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
CL2011000144A1 (es) Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros.
CL2011002745A1 (es) Compuestos derivados de acidos grasos poliinsaturados; metodo de preparacion; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de trastornos cardiovasculares, metabolicos e inflamatorios, tales como, artritis reumatoide, aterosclerosis, diabetes, dislipidemia, entre otras.
CL2008001180A1 (es) Un polvo bebestible instantaneo que comprende un agente de relleno y/o azucar recubiertas al menos parcialmente con un 0,1-5% de aceite de cadenas cortas de acidos grasos saturados de trigleceridos saturados c4-c14; capsula que comprende el polvo bebestible; metodo de produccion del polvo; kit que comprende un polvo bebestible.
AR084059A1 (es) Composicion para el cuidado de telas
MX377553B (es) Composicion farmaceutica estable y metodos de uso de la misma.
NZ595599A (en) Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
BR112012020666A2 (pt) "composições de óleo de ácido esteraridônico"
HN2010002735A (es) Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidrobenzo(1,4)dioxin-2-ilmetil)-sulfamida
AR061622A1 (es) Esteres del acido docosahexaenoico(dha), en particular el docosahexaenoato de piridin-3-il-metilo, metodo de preparacion, composicion farmaceutica que los contiene y su utilizacion en el tratamiento y prevencion de enfermedades cardiovasculares
AR064990A1 (es) Composiciones de grasas hidratadas y articulos de masa
NO20092131L (no) Fettsyrealkoholer
CO6630169A2 (es) Uso de aceites vegetales metilados estabilizados en frío como un coformulador químico agrícola
BRPI0804802A2 (pt) composição de lipìdio
CL2011002504A1 (es) Emulsion de encolado de papel que comprende agente de encolado de aceite vegetal maleatado en donde por lo menos 50% en peso de acidos grasos totales de los trigliceridos son monoinsaturados; agente de encolado de papel, proceso de preparacion de emulsion de encolado de papel; y uso de dicha emulsion.
ES2648120T3 (es) Nuevas formulaciones de ingrediente o ingredientes activos de origen vegetal o sus análogos sintéticos o de extracto o extractos de origen vegetal que los contienen, y de lecitina
PE20081491A1 (es) Composicion farmaceutica que comprende (r)-5,6-dimetoxi-2-[2,2,4,6,7-pentametil-3-(4-metilfenil)-2,3-dihidro-1-benzofuran-5-il)isoindolina y un componente lipofilico
SE0201566D0 (sv) New composition

Legal Events

Date Code Title Description
FD Application declared void or lapsed